Joseph M. Bateman, Jonathan M. E. Hughes, Matthieu Jouffroy, Peter J. Lindsay-Scott, Thomas M. McGuire, Damien Valette, Hilmar Weinmann
{"title":"The Discovery Process Chemistry (DPC) Model: A Cross-Pharma Perspective","authors":"Joseph M. Bateman, Jonathan M. E. Hughes, Matthieu Jouffroy, Peter J. Lindsay-Scott, Thomas M. McGuire, Damien Valette, Hilmar Weinmann","doi":"10.1021/acs.oprd.6c00218","DOIUrl":null,"url":null,"abstract":"<p>Discovery Process Chemistry (DPC) has emerged as a critical\r\nbridge\r\nbetween discovery chemistry and chemical development that allows more\r\nseamless progression of drug candidates to the clinic. DPC aims to\r\naccelerate projects by integrating SAR-enabling methodologies, scalable\r\nroute design to inform later campaigns, and early material delivery.\r\nCase studies from MSD, Johnson & Johnson, and AstraZeneca highlight\r\nhow this model can drive innovation and mitigate risks at the interface\r\nbetween medicinal and process chemistry groups. Keywords: discovery\r\nprocess, route scouting, early scale-up, and SAR enabling.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"30 8","pages":"2136–2148"},"PeriodicalIF":3.3000,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Process Research & Development","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.oprd.6c00218","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0
Abstract
Discovery Process Chemistry (DPC) has emerged as a critical
bridge
between discovery chemistry and chemical development that allows more
seamless progression of drug candidates to the clinic. DPC aims to
accelerate projects by integrating SAR-enabling methodologies, scalable
route design to inform later campaigns, and early material delivery.
Case studies from MSD, Johnson & Johnson, and AstraZeneca highlight
how this model can drive innovation and mitigate risks at the interface
between medicinal and process chemistry groups. Keywords: discovery
process, route scouting, early scale-up, and SAR enabling.
期刊介绍:
The journal Organic Process Research & Development serves as a communication tool between industrial chemists and chemists working in universities and research institutes. As such, it reports original work from the broad field of industrial process chemistry but also presents academic results that are relevant, or potentially relevant, to industrial applications. Process chemistry is the science that enables the safe, environmentally benign and ultimately economical manufacturing of organic compounds that are required in larger amounts to help address the needs of society. Consequently, the Journal encompasses every aspect of organic chemistry, including all aspects of catalysis, synthetic methodology development and synthetic strategy exploration, but also includes aspects from analytical and solid-state chemistry and chemical engineering, such as work-up tools,process safety, or flow-chemistry. The goal of development and optimization of chemical reactions and processes is their transfer to a larger scale; original work describing such studies and the actual implementation on scale is highly relevant to the journal. However, studies on new developments from either industry, research institutes or academia that have not yet been demonstrated on scale, but where an industrial utility can be expected and where the study has addressed important prerequisites for a scale-up and has given confidence into the reliability and practicality of the chemistry, also serve the mission of OPR&D as a communication tool between the different contributors to the field.